KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Evolent Health (EVH) EBITDA Margin (2016 - 2025)

Evolent Health (EVH) has 11 years of EBITDA Margin data on record, last reported at 2258.7% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 226350.0% year-over-year to 2258.7%; the TTM value through Dec 2025 reached 41.79%, down 3811.0%, while the annual FY2025 figure was 1009.68%, 101336.0% up from the prior year.
  • EBITDA Margin reached 2258.7% in Q4 2025 per EVH's latest filing, up from 5.76% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 2258.7% in Q4 2025 and bottomed at 14.93% in Q1 2025.
  • Average EBITDA Margin over 5 years is 108.01%, with a median of 4.68% recorded in 2021.
  • The widest YoY moves for EBITDA Margin: up 226350bps in 2025, down -1098bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 2.27% in 2021, then tumbled by -32bps to 3.0% in 2022, then plummeted by -148bps to 7.44% in 2023, then surged by 36bps to 4.79% in 2024, then surged by 47206bps to 2258.7% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 2258.7% in Q4 2025, 5.76% in Q3 2025, and 11.49% in Q2 2025.